![GSK to buy Nuvalent for $10.6B [titlebase] in a Historic Deal, Expanding its Oncology Portfolio](https://www.floriparesort.com/wp-content/uploads/2026/06/gsk-to-buy-nuvalent-for-10-6b-titlebase-in-a-historic-deal-expanding-its-oncology-portfolio.webp)
floriparesort.com – 09 June 2026 | GSK has announced its plan to buy Nuvalent for $10.6B [titlebase], a US-listed cancer drug developer, in an all-cash deal valued at approximately $10.6 billion. This acquisition marks GSK’s largest deal in more than a decade and is expected to expand its oncology portfolio significantly. The deal values Nuvalent at $124 per share, representing a 40% premium to Monday’s closing price. To buy Nuvalent for $10.6B [titlebase] is a strategic move by GSK, as it looks to strengthen its position in the oncology market.
The acquisition of Nuvalent is a major shift in GSK’s strategy, as it moves away from smaller bolt-on deals. GSK CEO Luke Miels stated that the deal offers significant new treatment options for lung cancer patients and creates a platform to expand its experimental antibody-drug conjugate Ris-Rez, which is currently in late-stage testing. To buy Nuvalent for $10.6B [titlebase] is a bold move, and investors are watching closely to see how this deal will impact GSK’s future growth.
![Vanessa Trump Diagnosed w/ breast cancer [titlebase]: Understanding the Disease and Its Implications](https://www.floriparesort.com/wp-content/uploads/2026/05/vanessa-trump-diagnosed-w-breast-cancer-titlebase-understanding-the-disease-and-its-implications-60x60.webp)
GSK has been focused on expanding its oncology portfolio, and the acquisition of Nuvalent is a significant step in this direction. In 2025, GSK saw notable growth across its oncology portfolio, with sales income across the disease area swelling by 43% to just under £2 billion compared to 2024. To buy Nuvalent for $10.6B [titlebase] is expected to further boost GSK’s oncology sales and help the company achieve its target of £40 billion in annual revenue by 2031.
![CT Reports 3 Child Deaths [titlebase]: A Growing Concern of Diphenhydramine Overdose](https://www.floriparesort.com/wp-content/uploads/2026/06/ct-reports-3-child-deaths-titlebase-a-growing-concern-of-diphenhydramine-overdose-60x60.webp)
The deal has been well-received by investors, with Nuvalent’s stock soaring in premarket trading, up 38.9% to trade at $122.88. GSK shares, however, slipped over 3% in early trading in London. To buy Nuvalent for $10.6B [titlebase] is a significant investment, and investors are waiting to see how this deal will impact GSK’s financial performance in the long run.
![WHO Chief Visits Ebola Zone [titlebase]: A Desperate Bid to Contain the Outbreak](https://www.floriparesort.com/wp-content/uploads/2026/05/who-chief-visits-ebola-zone-titlebase-a-desperate-bid-to-contain-the-outbreak-60x60.webp)
In conclusion, GSK’s decision to buy Nuvalent for $10.6B [titlebase] is a strategic move that is expected to expand its oncology portfolio and strengthen its position in the market. The deal is a significant investment, and investors are watching closely to see how it will impact GSK’s future growth. To buy Nuvalent for $10.6B [titlebase] is a historic deal that marks a new chapter in GSK’s oncology journey.